Myrtelle has announced that their gene therapy, rAAV-Olig001-ASPA for the treatment of Canavan disease has been chosen for the Support for Clinical Trials Advancing Rare Disease Therapeutics (START) Pilot Program.
“Acceptance into the START pilot program is an honor in that it recognizes rAAV-Olig001-ASPA as a candidate for accelerated development as a potential treatment for Canavan disease. Opening the lines of communications beyond traditional meeting pathways provides the opportunity to quickly address development issues that would otherwise delay progression to market application”, said Nancy Barone Kribbs, PhD, Senior Vice President of Global Regulatory Affairs at Myrtelle.
To read press release: Myrtelle press release
